Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of XmAb24306 Alone and With Atezolizumab in Advanced Solid Tumors
NCT04250155Phase 1Completed
- Sponsor
- Genentech
- Start
- Mar 2020
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 1, open-label trial of efbalropendekin alfa in solid tumor (4 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events at 4 years. Started Mar 2020; status: completed.
02
Drugs
efbalropendekin alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04250155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250155.